| Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer G Serna, F Ruiz-Pace, J Hernando, L Alonso, R Fasani, S Landolfi, ... Annals of Oncology 31 (10), 1366-1375, 2020 | 85 | 2020 |
| Analysis of mutant allele fractions in driver genes in colorectal cancer–biological and clinical insights R Dienstmann, E Elez, G Argiles, I Matos, E Sanz‐Garcia, C Ortiz, ... Molecular oncology 11 (9), 1263-1272, 2017 | 33 | 2017 |
| Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer G Serna, F Ruiz-Pace, F Cecchi, R Fasani, J Jimenez, S Thyparambil, ... Scientific reports 9 (1), 13568, 2019 | 21 | 2019 |
| Evolving landscape of molecular prescreening strategies for oncology early clinical trials R Dienstmann, E Garralda, S Aguilar, G Sala, C Viaplana, F Ruiz-Pace, ... JCO Precision Oncology 4, 505-513, 2020 | 16 | 2020 |
| PI3K activation promotes resistance to eribulin in HER2-negative breast cancer British Journal of Cancer, https://doi.org/10.1038/s41416-021-01293, 2021 | 13* | 2021 |
| Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer V Rodriguez-Freixinos, F Ruiz-Pace, L Fariñas-Madrid, ... ESMO open 4 (2), e000444, 2019 | 13 | 2019 |
| Positive impact of a faecal-based screening programme on colorectal cancer mortality risk G Ibáñez-Sanz, N Milà, C Vidal, J Rocamora, V Moreno, ... PLoS One 16 (6), e0253369, 2021 | 12 | 2021 |
| Future prospects of colorectal cancer screening: Characterizing interval cancers G Ibáñez-Sanz, R Sanz-Pamplona, M Garcia, Msic-Sc Research Group Cancers 13 (6), 1328, 2021 | 8 | 2021 |
| Immune profile and outcomes of patients (pts) with gynecological malignancies (GYN) enrolled in early phases immunotherapy (IO) trials. V Rodriguez Freixinos, A Garcia, R Fasani, J Castellvi, F Ruiz-Pace, ... Journal of Clinical Oncology 36 (15_suppl), 5595-5595, 2018 | 8 | 2018 |
| Comprehensive profiling of biliary tract cancers (BTC) to reveal molecular heterogeneity with implications for matched targeted therapies (MTT). T Sauri, T Macarulla, G Cabrera, H Verdaguer, F Ruiz, A Vivancos, ... Journal of Clinical Oncology 34 (15_suppl), 4085-4085, 2016 | 7 | 2016 |
| A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort A Gunda, C Basavaraj, M Adinarayan, R Kolli, MS Eshwaraiah, C Saura, ... The Breast 63, 1-8, 2022 | 6 | 2022 |
| Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC). M Oliveira, R Dienstmann, M Bellet, JM Perez-Garcia, P Gomez-Pardo, ... Journal of Clinical Oncology 34 (15_suppl), 528-528, 2016 | 4 | 2016 |
| A Comprehensive Biomarker analysis of microsatellite Unstable/Mismatch repair deficient colorectal Cancer cohort treated with immunotherapy E Élez, N Mulet-Margalef, M Sanso, F Ruiz-Pace, FM Mancuso, R Comas, ... International Journal of Molecular Sciences 24 (1), 118, 2022 | 3 | 2022 |
| Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC). M Oliveira, F Ruiz-Pace, J Matito, R Perez-Lopez, A Suñol, M Bellet, ... Journal of Clinical Oncology 37 (15_suppl), 1075-1075, 2019 | 3 | 2019 |
| 731 Biomarker analysis of the phase 2 study of pembrolizumab in combination with doxorubicin in advanced endometrial cancer: TOPIC trial/VHIO10001 JM Piulats, L Fariñas-Madrid, M Santacana, MJR Pérez, A Redondo, ... International Journal of Gynecologic Cancer 31 (Suppl 3), 2021 | 2 | 2021 |
| 798P A phase II study of pembrolizumab (P) in combination with doxorubicin (D) in advanced endometrial cancer (AEC): TOPIC trial/VHIO10001 L Farinas-Madrid, MJ Rubio, A Redondo, GV Javierre, AY Esteban, ... Annals of Oncology 32, S761-S762, 2021 | 2 | 2021 |
| FGFR 360° resistance: Establishing a translational research framework in FGFR-altered (FGFRalt) patients (pt) treated with fibroblast growth factor receptor inhibitors (FGFRinh) C Hierro, M Sánchez-Guixé, F Ruiz-Pace, J Jimenez, L Maynes, A Azaro, ... Annals of Oncology 28, v575, 2017 | 2 | 2017 |
| Evolving landscape of molecular prescreening strategies for oncology early clinical trials. JCO Precis Oncol 2020; 4: PO. 19.00398 R Dienstmann, E Garralda, S Aguilar, G Sala, C Viaplana, F Ruiz-Pace | 2 | |
| Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. ESMO Open 2019; 4 (2): e000444 V Rodriguez-Freixinos, F Ruiz-Pace, L Fariñas-Madrid | 2 | |
| Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre … N Mulet Margalef, C Castillo, M Mosteiro, X Pérez, S Aguilar, F Ruíz‐Pace, ... Molecular Oncology 17 (9), 1908-1916, 2023 | 1 | 2023 |
Cristina ViaplanaVall d'Hebron Institute of Oncology (VHIO)Verified email at vhio.net
